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INTRODUCTION
Dementia is defined as a loss of memory and cognitive func-
tion that results in a decline in the activities of daily living and 
is a social and economic burden on patients, families, and the 
government.1-3 Dementia is commonly attributed to Alzheim-
er’s disease (AD) (25%–75%), vascular dementia (20%–30%), 
frontotemporal dementia, and dementia with Lewy bodies 
(<5%).4 Patients with dementia commonly have more than one 
comorbidity, which significantly impacts the treatment for de-
mentia itself and overall quality of life.5 According to the World 
Alzheimer Report 2018, dementia affects as many as 50 mil-
lion people worldwide. This number is estimated to increase 
to 82 million by 2030 and to almost triple to 152 million by 
2050.1,6 However, individual studies on the prevalence of this 
condition have reported conflicting results; the prevalence of 
dementia is stable in some studies and increasing or decreasing 
in others.7-13 
The burden of dementia on daily life and financial costs is 
well-known. The average year lived with disability is 7.4 years, 
which ranks dementia as the second most difficult chronic dis-
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ease.14 Caregivers spend an average of 3.6 and 2.6 hours per 
day assisting patients with activities of daily living and caring for 
the patient, respectively.15 As such, dementia represents a sig-
nificant health burden and should be a high priority in health 
policy. 
Korea will become an aged society (20.8% of the population 
≥65 years) by 2026.16 It has taken Korea 17 years for the pro-
portion of the population >65 years of age to increase from 7% 
to 14%, whereas the same increase took France and Japan 115 
and 24 years, respectively.17 The Korean Ministry of Health and 
Welfare estimated that the prevalence of dementia will be 
15% in 2050.18 The Nationwide Survey on Dementia Epidemi-
ology of Korea (NaSDEK) was conducted in 2008, 2012, and 
2016 to investigate the epidemiologic characteristics of de-
mentia and to estimate its prevalence. These cross-sectional 
studies determined that the prevalence of dementia was 8.1% 
and 9.5% in 2008 and 2016, respectively, and showed an increas-
ing trend.19-21 Until recently, only a few studies have examined 
the prevalence of and hospital utilization for dementia.22-25 It 
can, however, be difficult to conduct interview or questionnaire-
based cross-sectional studies on dementia, because cognitive 
functional decline and/or memory impairment in these pa-
tients may influence the quality of the data on epidemiologic 
characteristics, comorbidities, and medication utilized. 
The National Health Insurance System (NHIS) of Korea re-
quires data on the admitting diagnosis and comorbidities of 
patients who make insurance claims. In this study, we analyzed 
the prevalence of dementia between 2008 and 2016 based on 
NHIS claims data for dementia.
MATERIALS AND METHODS
Study design and population
We collected 2008–2016 hospital utilization data from the Health 
Insurance Review & Assessment (HIRA) database. The claims 
database contains information on the date of visit; demographic 
characteristics; main and sub-diagnosis codes during out-pa-
tient, admission, or emergency care; medication history; and 
patient expenditures. All patients who visited a hospital for de-
mentia were included in our study.
Using the International Classification of Diseases 10th Revi-
sion (ICD-10) code, patients with dementia were classified as 
follows: 1) AD (F00, G30.0, G30.1, G30.8, G30.9), 2) vascular 
dementia (F01), 3) other (F02, G31.0, A81.0) and unclassified 
dementia (F03, G31.82). Comorbidities were identified based 
on hospital utilization for hypertension (I10–15), cardiovascu-
lar disease (I20–25), diabetes (E10–14), and stroke (G45–46, 
I60–64, I67–69). Patients who visited an out-patient clinic or 
were admitted for dementia and/or a comorbidity more than 
once each calendar year were defined as dementia cases and 
dementia cases with comorbidity, respectively. Patients were 
classified according to their main and sub-diagnostic codes. 
This study was approved by the Institutional Review Boards 
of Yonsei University Health System (2018-0418-001) and HIRA 
Service, which waived the requirement for informed consent.
Statistical analysis
Dementia cases were stratified by age (< 60, 60–64, 65–69, 70–
74, 75–79, 80–84, ≥85) and sex. Crude prevalence was estimated 
using the mid-year populations for each year, which were de-
rived from population census data. Age- and/or sex-standard-
ized prevalence from 2008 to 2016 was estimated using mid-
year population data for 2008. Prevalence and 95% confidence 
interval (CI) were estimated using Proc STDRATE in SAS ver-
sion 9.4 (SAS Institute Inc., Cary, NC, USA). A log normal distri-
bution was used to estimate 95% CIs. Subgroup analyses were 
performed for age and sex.
Differences in the prevalence of dementia during the study 
period were estimated using a generalized linear model with log 
binomial distribution. We analyzed de-identified claims data 
from the HIRA system. All statistical analyses were performed 
with SAS version 9.4 (SAS Institute Inc.).
RESULTS
We identified 176746 dementia cases in 2008; this number in-
creased continuously over the course of the study period (Ta-
ble 1). Hospital utilization for dementia was more prevalent 
among female patients, especially among those who were 70–
79 years of age, particularly between 2008 and 2012. Female 
patients ≥85 years of age comprised a significant majority of 
the insurance claims after 2013. Among patients ≥85 years of 
age, hospital utilization for dementia was 4.3 times higher in 
2016 than that in 2008. The most common dementia subtype 
was AD, and the most common comorbidity was hypertension. 
The proportion of patients with diabetes increased continuous-
ly from 31.6% to 37.0% from 2008 to 2016, respectively, whereas 
the proportion of patients with stroke followed a decreasing 
trend (Table 2). 
Age- and sex-standardized prevalence increased statistical-
ly significantly by 1.34 times (0.39 vs. 0.54 per 1000 population 
in 2008 and 2016, respectively) and 2.02 times (31.28 vs. 61.98 
per 1000 population in 2008 and 2016, respectively) in patients 
under <65 years and ≥65 years of age, respectively (Table 3). 
After stratifying the cases according to sex, the age-standard-
ized prevalence increased across all age groups. Among males 
≥65 years of age, the age-standardized prevalence increased 
from 22.1 to 39.8 per 1000 population from 2008 to 2016, re-
spectively (Table 4). Among females ≥65 years of age, the age-
standardized prevalence increased from 37.4 to 77.0 per 1000 
population from 2008 to 2016, respectively. Among males <65 
years of age, the age-standardized prevalence increased from 
0.39 to 0.52 per 1000 population from 2008 to 2016, respective-
ly, whereas females <65 years of age showed a similar increase 
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from 0.40 to 0.56 per 1000 population from 2008 to 2016, respec-
tively. After 2011, the prevalence of dementia was significantly 
higher in females (Supplementary Table 1, only online).
Fig. 1 shows the sex-standardized prevalence according to 
age group. Although sex-standardized prevalence increased 
across all age groups, a prominent increase in prevalence was 
observed in patients ≥70 years of age. In both male and female 
patients, the prevalence of dementia increased across all age 
groups over time. The highest increase was observed in the 
group ≥85 years of age (Supplementary Table 2, only online). 
Across age groups, females showed a higher prevalence of de-
mentia, except among patients <60 years of age. 




















<60 years 9244 (5.2) 10476 (4.8) 11621 (4.4) 12170 (3.9) 12719 (3.6) 12929 (3.3) 13263 (3.0) 13429 (2.8) 13904 (2.6)
60–64 years 8419 (4.8) 9832 (4.5) 11574 (4.4) 12911 (4.2) 13193 (3.7) 13592 (3.4) 13557 (3.1) 14210 (3.0) 15422 (2.9)
65–69 years 19564 (11.1) 22681 (10.4) 25258 (9.6) 27060 (8.7) 27511 (7.8) 26829 (6.8) 27896 (6.4) 29642 (6.2) 31593 (6.0)
70–74 years 31879 (18.0) 38772 (17.8) 44967 (17.1) 51427 (16.6) 56993 (16.1) 62570 (15.8) 64850 (14.9) 66328 (13.8) 66858 (12.6)
75–79 years 39734 (22.5) 48824 (22.5) 59289 (22.6) 71008 (22.9) 82389 (23.3) 92554 (23.4) 101426 (23.3) 110303 (22.9) 117293 (22.1)
80–84 years 35447 (20.1) 44855 (20.6) 56476 (21.5) 68958 (22.3) 80926 (22.9) 92883 (23.5) 104707 (24.0) 119019 (24.7) 136354 (25.7)
≥85 years 32459 (18.4) 41883 (19.3) 53086 (20.2) 66359 (21.4) 79448 (22.5) 94501 (23.9) 110450 (25.3) 128678 (26.7) 148845 (28.1)
Sex
Male 54318 (30.7) 65998 (30.4) 78872 (30.1) 90938 (29.3) 101865 (28.8) 113071 (28.6) 123992 (28.4) 136920 (28.4) 150785 (28.4)
Female 122428 (69.3) 151325 (69.6) 183399 (69.9) 218955 (70.7) 251314 (71.2) 282787 (71.4) 312157 (71.6) 344689 (71.6) 379484 (71.6)
Dementia subtype*
Alzheimer’s 115521 (65.4) 147305 (67.8) 179155 (68.3) 217067 (70.0) 263177 (74.5) 306563 (77.4) 346117 (79.4) 401925 (83.5) 456358 (86.1)
Vascular 26623 (15.1) 32304 (14.9) 37724 (14.4) 43667 (14.1) 46071 (13.0) 46699 (11.8) 49225 (11.3) 52660 (10.9) 56306 (10.6)
Others 59680 (33.8) 65853 (30.3) 80576 (30.7) 93406 (30.1) 96542 (27.3) 94169 (23.8) 96014 (22.0) 91179 (18.9) 70422 (13.3)
The values in parentheses are percentages.
*Percentages may add up to more than 100% due to multiple diagnoses in the same patient.




















Hypertension 112593 (63.7) 139248 (64.1) 169363 (64.6) 200241 (64.6) 232515 (65.8) 263157 (66.5) 291584 (66.9) 323178 (67.1) 358281 (67.6)
Cardiovascular disease 30102 (17.0) 37298 (17.2) 44397 (16.9) 50914 (16.4) 59002 (16.7) 67236 (17.0) 77468 (17.8) 86417 (17.9) 95076 (17.9)
Diabetes 55914 (31.6) 69766 (32.1) 85240 (32.5) 102307 (33.0) 120258 (34.1) 137512 (34.7) 154158 (35.3) 174583 (36.2) 196158 (37.0)
Stroke 79807 (45.2) 96071 (44.2) 114005 (43.5) 129124 (41.7) 142456 (40.3) 155665 (39.3) 168241 (38.6) 182436 (37.9) 198687 (37.5)
The values in parentheses are percentages. Percentages may add up to more than 100% due to multiple diagnoses in the same patient. 
Table 3. Crude and Standardized Prevalence of Dementia per 1000 Population from 2008 to 2016
Year
<65 years ≥65 years
Crude Standardized* Prevalence ratio† Crude Standardized* Prevalence ratio†
2008 0.39 (0.39–0.4) 0.39 (0.39–0.4) Reference 31.28 (31.12–31.43) 31.28 (61.81–62.15) Reference
2009 0.45 (0.45–0.46) 0.44 (0.44–0.45) 1.13 (1.1–1.15) 37.27 (37.1–37.43) 36.52 (59.2–59.55) 1.17 (1.16–1.17)
2010 0.52 (0.51–0.52) 0.49 (0.49–0.5) 1.26 (1.23–1.28) 43.88 (43.7–44.05) 42.01 (56.39–56.74) 1.34 (1.33–1.35)
2011 0.55 (0.55–0.56) 0.53 (0.52–0.53) 1.34 (1.32–1.37) 50.46 (50.27–50.64) 47.38 (54.06–54.41) 1.51 (1.5–1.52)
2012 0.57 (0.57–0.58) 0.53 (0.53–0.54) 1.36 (1.33–1.38) 55.26 (55.07–55.45) 51.05 (50.88–51.23) 1.64 (1.63–1.65)
2013 0.59 (0.58–0.59) 0.54 (0.53–0.55) 1.37 (1.34–1.40) 59.64 (59.45–59.83) 54.23 (54.06–54.41) 1.75 (1.74–1.76)
2014 0.59 (0.59– 0.6) 0.53 (0.53–0.54) 1.35 (1.32–1.37) 63.34 (63.14–63.53) 56.56 (56.39–56.74) 1.83 (1.82–1.84)
2015 0.61 (0.6–0.62) 0.53 (0.52–0.53) 1.32 (1.30–1.35) 67.56 (67.37–67.76) 59.38 (59.2–59.55) 1.93 (1.92–1.94)
2016 0.65 (0.64–0.65) 0.54 (0.53–0.54) 1.34 (1.32–1.37) 72.18 (71.98–72.38) 61.98 (61.81–62.15) 2.02 (2.01–2.03)
The values in parentheses are the 95% confidence intervals.
*For estimation of age- and sex-standardized prevalence, the mid-year population number of 2008 was used, †Age- and sex-standardized prevalence ratios used 
a log binomial linear mixed model. 
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DISCUSSION
Our study demonstrated that the number of patients with de-
mentia in Korea tripled from 176746 to 530269 from 2008 to 
2016. The age- and sex-standardized prevalence of dementia 
among patients ≥65 years of age increased from 3.13% to 6.2% 
from 2008 to 2016, respectively.
According to the World Alzheimer Report 2018, North Afri-
ca/Middle East and Latin America had the highest prevalence 
of standardized dementia among patients ≥60 years of age at 
8.7% and 8.4%, respectively. In contrast, Central Europe had 
the lowest prevalence at 4.7%. All other regions had prevalence 
rates between 5.6%–7.6%.26 Further, while the data from these 
studies show mixed results,27 data from high-income countries 
like Germany, the United States, Spain, and England have high-
lighted stable10 or declining11-13 rates, respectively.
Although age plays a role in the prevalence of dementia, our 
findings showed that the prevalence of dementia in Korea was 
lower than that in other countries. Both our data and the NaS-
DEK data demonstrated an increasing trend in the prevalence 
of dementia in Korea. However, when we compared study find-
ings, our prevalence were lower than those in the NaSDEK 
study, especially for the year 2008.18,21 Interestingly, while there 
was a difference in the prevalence of dementia between our 
study and the NaSDEK (e.g., 2008: 1.0% vs. 3.6% among patients 
65–69 years of age and 2.2% vs. 5.2% among patients 70–74 
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0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3
4.1 4.6
22.1 25.5 28.9
31.7 32.5 35.1 36.5 37.6
38.2
Year


































10.1 11.8 13.3 14.4 14.6 13.6 13.5 13.6 14.2
5.1 5.6 5.4 5.5 5.1 4.9 4.9
Table 4. Age-Standardized Prevalence of Dementia per 1000 Population from 2008 to 2016 Analyzed according to Sex among Patients ≥65 Years of Age 
Year
Male Female Female-to-male 
prevalence ratio†Crude Standardized* Prevalence ratio† Crude Standardized* Prevalence ratio†
2008 22.1 (21.94–22.35) 22.1 (21.9–22.35) Reference 37.4 (37.22–37.65) 37.4 (37.22–37.65) Reference 1.37 (1.35–1.38)
2009 26.1 (25.89–26.33) 25.5 (25.32–25.75) 1.15 (1.14–1.17) 44.9 (44.62–45.09) 43.9 (43.71–44.17) 1.17 (1.16–1.18) 1.39 (1.37–1.40)
2010 30.4 (30.17–30.63) 29.1 (28.87–29.31) 1.31 (1.30–1.33) 53.1 (52.86–53.36) 50.7 (50.48–50.96) 1.35 (1.34–1.36) 1.40 (1.38–1.41)
2011 34.1 (33.82–34.29) 32.0 (31.76–32.21) 1.44 (1.43–1.46) 61.8 (61.55–62.08) 57.8 (57.52–58.02) 1.54 (1.53–1.55) 1.44 (1.43–1.45)
2012 36.7 (36.43–36.91) 33.8 (33.58–34.02) 1.53 (1.51–1.55) 68.3 (68.03–68.58) 62.7 (62.43–62.94) 1.68 (1.67–1.69) 1.46 (1.45–1.48)
2013 39.0 (38.79–39.27) 35.4 (35.15–35.59) 1.61 (1.59–1.63) 74.3 (74.01–74.57) 67.0 (66.7–67.21) 1.80 (1.79–1.81) 1.48 (1.47–1.49)
2014 41.0 (40.80–41.29) 36.5 (36.31–36.75) 1.66 (1.64–1.68) 79.4 (79.08–79.65) 70.1 (69.82–70.33) 1.89 (1.88–1.91) 1.50 (1.49–1.51)
2015 43.7 (43.48–43.96) 38.3 (38.11–38.54) 1.75 (1.73–1.76) 84.9 (84.59–85.17) 73.6 (73.32–73.83) 2.00 (1.98–2.01) 1.50 (1.49–1.51)
2016 46.5 (46.23–46.72) 39.8 (39.56–39.99) 1.81 (1.80–1.83) 91.0 (90.71–91.3) 77.0 (76.71–77.21) 2.11 (2.09–2.12) 1.50 (1.49–1.51)
The values in parentheses are the 95% confidence intervals.
*For estimation of age-standardized prevalence, the mid-year population of 2008 was used, †Age-adjusted prevalence ratio.  
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years of age), the prevalence estimates for these same age 
groups among <75 years of age were exactly the same in 2016 
(1.4% and 3.8% among patients 65–69 and 70–74 years of age, 
respectively). Nevertheless, the difference in prevalence per-
sisted among patients ≥75 years of age in 2016 (8.3% vs. 11.9%, 
15.4% vs. 21.1%, and 25.7% vs. 38.4% among patients aged 75–
79, 80–84, ≥85 years of age, respectively). Overall, our study dem-
onstrated a lower prevalence of dementia than NaSDEK.21 
Because we used health insurance claims data, patients with 
dementia who did not visit a hospital may have been excluded 
from our prevalence estimation. The prevalence of dementia 
may be underestimated in situations where there is a low so-
cial interest in dementia screening and treatment. In our study, 
the rapid increase in prevalence (14% average annual increase) 
and discrepancies in dementia prevalence between the NaS-
DEK study and our study may be caused by hospital underuti-
lization, especially during the early study period. While there is 
a strong push towards improving dementia coverage and im-
proving the quality of life of patients with dementia, our study 
strongly suggests that hospital underutilization for dementia 
still exists, particularly among patients ≥75 years of age. 
In our study, the most common dementia subtype was AD, 
followed by vascular dementia and other dementias. Consis-
tent with other studies,18,28 the proportion of AD continuously 
increased from 65.4% to 86.1% from 2008 to 2016, whereas the 
proportion of vascular dementia decreased from 15.1% to 
10.6%. Throughout the study period, dementia was also more 
prevalent in females. This corroborates other studies that have 
reported that the prevalence of dementia is 19–29% higher in 
females than in males.6,26,29
Dementia commonly occurs with other comorbidities. Co-
morbidities, such as hypertension, diabetes, and cerebrovascu-
lar disease, can exacerbate the progression of dementia, partic-
ularly in terms of cognitive decline. Dementia also adversely 
affects the quality of care, treatment, and prognosis of these co-
morbidities.30,31 As such, it is necessary to actively screen for 
and manage comorbidities to delay the progression of disabil-
ity from dementia. A previous study in Korea that used hospi-
tal-based registry data also demonstrated that 48.9% and 22.3% 
of 1786 patients with AD had hypertension and diabetes, re-
spectively.32 A recent study in Taiwan reported that the propor-
tion of subjects with at least three comorbidities was higher in 
individuals with cognitive impairment (mild cognitive impaire-
ment 20.9%, dementia 27.2%) than in those with normal cogni-
tion (15.6%).33 The same study also identified hypertension 
and diabetes as the most common comorbidities of dementia. 
Our results agreed with their data in that hypertension was the 
most common comorbidity (63.7% and 67.6% in 2008 and 
2016, respectively), followed by diabetes and stroke. The prev-
alence of diabetes increased from 31.6% to 37.0% from 2008 to 
2016, respectively, whereas the prevalence of stroke decreased 
over the same period. This finding coincides with a decreas-
ing trend in stroke in Korea.34 
Our study is the first to estimate the prevalence of dementia 
and its comorbidities using NIH claims data; however, our study 
has some limitations. First, the prevalence estimated in this 
study may be underestimated because claims data are collect-
ed for cost calculation and reimbursement rather than disease 
surveillance. As such, patients who did not visit medical insti-
tutions to seek care for dementia were not included in our cal-
culations. This is especially important for the earlier time peri-
ods of our study, when hospital utilization for dementia was 
likely lower. However, our data eventually matched the data 
published in a national epidemiological survey, which may be 
due to active screening and treatment of dementia in later 
years. In 2011, the Korean government passed a dementia man-
agement law, established dementia centers in all communi-
ties, and launched a mandatory dementia screening program. 
These might have affected the hospital utilization for demen-
tia. In the future, longitudinal claims data may allow for more 
accurate prevalence estimates. Second, our study may have 
misclassified dementia cases and their subtypes.35 We defined 
dementia cases as patients who visited medical institutions 
more than once each calendar year. Thus, classification of de-
mentia and its subtype was likely to be inaccurate, and the re-
sults might be biased. 
In conclusion, our study demonstrated that the prevalence 
of dementia in Korea increased significantly from 2008 to 
2016. Enhanced programs that screen and treat dementia and 
its associated comorbidities are necessary to prevent demen-
tia progression and to improve the overall quality of care. In ad-
dition, although limitations exist, our study suggested that claims 
data may be utilized to estimate the prevalence of dementia. 
Because claims data cover the entire population of Korea, the 
data may be a valuable research tool for tracking trends in de-
mentia prevalence and its subtypes.  
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